EUCTR2010-020345-27-GB进行中（未招募）1 期
AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY
CB BioSciences INC.0 个研究点目标入组 720 人开始时间: 2011年2月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 720
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •An Independent Ethics Committee (IEC)/Institutional Review Board (IRB) approved written informed consent signed and dated by the subject or by parent(s) or legally acceptable representative. The consent form or a specific assent form, where required, will be signed and dated by minors. In countries and sites where a DNA analysis is accepted, an additional Informed Consent form will have to be signed by subjects coming from N01358. Deoxyribonucleic acid analysis will be performed only in adults, and the subject can withdraw consent to the use of the sample at any time. Mentally impaired subjects will be excluded. In case the consent is withdrawn, the site must request the destruction of the sample.
- •Male/female subject from 16 years or older. Subject under 18 years may only be included where legally permitted and ethically accepted.
- •Subject completed the Treatment Period of N01358 or the Evaluation Period of N01258.
- •Subject for whom the Investigator believes a reasonable benefit from the long-term administration of BRV may be expected.
- •Female subject without childbearing potential (premenarcheal, postmenopausal for at least 2 years, bilateral oophorectomy or tubal ligation, complete hysterectomy) are eligible. Female subject with childbearing potential are eligible if they use a medically accepted contraceptive method. Oral or depot contraceptive treatment with at least ethinylestradiol 30µg per intake (or ethinylestradiol 50µg per intake if associated with any strong enzyme inducer [eg, carbamazepine, phenobarbital, primidone, phenytoin, oxcarbazepine, St. John’s Wort, rifampicin]), monogamous relationship with vasectomized partner, or double-barrier contraception are acceptable methods. The subject must understand the consequences and potential risks of inadequately protected sexual activity, be educated about and understand the proper use of contraceptive methods, and undertake to inform the Investigator of any potential change in status. Abstinence will be considered as an acceptable method of contraception if the Investigator can document that the subject agrees to be compliant.
- •Subject/legally acceptable representative considered as reliable and capable of adhering to
- •the protocol (eg, able to understand and complete diaries and questionnaires), visit schedule, or medication intake according to the judgment of the Investigator.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subject has developed hypersensitivity to any components of the investigational medicinal product (IMP) or comparative drugs as stated in this protocol during the course of the core studies
- •Severe medical, neurological, or psychiatric disorders, or laboratory values which may have an impact on the safety of the subject
- •Poor compliance with the visit schedule or medication intake in the previous BRV studies
- •Planned participation in any other clinical study of another investigational drug or device during this study
- •Pregnant or lactating woman
- •Any medical condition which, in the Investigator’s opinion, warrants exclusion
- •Subject has a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response (Yes”) to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening
研究者
相似试验
进行中（未招募）
1 期
An open-label (treatment received will be known) follow-up study to evaluate the safety and efficacy of brivaracetam when used treating partial onset seizures for a long period of time in patients with epilepsy (=16 years to 80 years)EpilepsyEUCTR2010-020345-27-SECB BIOSCIENCES, INC.720
进行中（未招募）
1 期
An open-label (treatment received will be known) follow-up study to evaluate the safety and efficacy of brivaracetam when used treating seizures for a long period of time in patients with epilepsy (aged 16 years or older)EpilepsyEUCTR2010-020345-27-BGCB BIOSCIENCES, INC.720
进行中（未招募）
1 期
An Open-Label Trial to look at the long-term safety and effectiveness of Brivaracetam used in addition to the subjects main treatment in subjects aged 16 years or older with epilepsyonpyschotic Behavioural Side Effects in Subjects With EpilepsyMedDRA version: 14.1Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-000827-42-ESCB Pharma SA26
进行中（未招募）
1 期
An open-label (treatment received will be known) follow-up study to evaluate the safety and efficacy of brivaracetam when used treating partial onset seizures for a long period of time in patients with epilepsy (=16 years to 80 years)MedDRA version: 18.1 Level: PT Classification code 10015037 Term: Epilepsy System Organ Class: 10029205 - Nervous system disordersEpilepsyEUCTR2010-020345-27-CZCB BIOSCIENCES, INC.720
进行中（未招募）
不适用
An Open-Label Trial to look at the long-term safety and effectiveness ofBrivaracetam used in addition to the subjects main treatment in subjectsaged 16 years or older with epilepsyonpyschotic Behavioural Side Effects in Subjects With EpilepsyMedDRA version: 14.1Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2012-000827-42-ITCB PHARMA SA/NV.650